A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Pacific Biosciences of California Inc.’s current trading price is -11.27% away from its 52-week high, while its distance from the 52-week low is 227.27%. The stock’s price range for this time frame has been between $3.85 and $14.20. The trading volume of the company’s shares in the Healthcare reached around 1.4 million for the day, which was evidently lower than the average daily volume of 3.64 million over the last three months.
Currently, the stock price of Pacific Biosciences of California Inc. (PACB) is $12.60. In the most recent trading session, the stock underwent a significant upswing, peaking at $13.43 after opening at $12.67. The stock touched a low of $12.65 before closing at $13.06.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Pacific Biosciences of California Inc.’s stock has had a calm market performance. The 1-year high for the company’s stock was $14.20 on 08/11/22, and the lowest price during the same period was recorded at $3.85 on 06/14/22.
How Financial Performance Impacts Market Capitalization
Pacific Biosciences of California Inc. (PACB) has experienced a quarterly rise of 35.19% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.26B and boasts a workforce of 769 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.47, with a change in price of +4.79. Similarly, Pacific Biosciences of California Inc. recorded 3,981,948 in trading volume during the last 100 days, posting a change of +61.50%.
How PACB’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 1.30. Similarly, the long-term debt-to-equity ratio is also 1.30.
PACB Stock Stochastic Average
The raw stochastic average for Pacific Biosciences of California Inc. over the last 50 days is presently at 83.94%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 76.27%. Further, the company’s Stochastic %K and %D values for the last 20 days were 86.70% and 91.63%, respectively.
PACB Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price increase of 54.03%. However, over the past six months, we’ve seen a weaker performance of 18.76%. The price of PACB fallen by 16.34% over the last 30 days. And in the last five days, it has surged by 3.03%.
